Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AstraZeneca, FibroGen deal takes aim at anemia
September 2013
SHARING OPTIONS:

LONDON—AstraZeneca PLC has inked a strategic partnership with FibroGen to develop and commercialize FG-4592, an oral compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The agreement will focus on U.S., China and all other major markets, excluding the Commonwealth of Independent States, the Middle East, South Africa, Japan and Europe. Both companies can exercise an option to extend the collaboration to other anemia indications. AstraZeneca will pay $350 million in upfront and subsequent non-contingent payments, with the potential for up to $465 million in development-related milestone payments. FibroGen will be eligible for sales-related milestones as well as tiered royalty payments on future sales in the low 20-percent range. AstraZeneca will lead U.S. commercialization, while FibroGen will handle clinical trials, regulatory matters, manufacturing and medical affairs in China, with AstraZeneca handling commercial distribution.  

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.